A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo. Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Brief Title

The Hemodynamic Response to Prolonged Dobutamine Infusion

Official Title

Brief Summary

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is<br /> thought to play a major role in the pathogenesis of diseases such as congestive heart<br /> failure. However, currently, there is no in vivo model that will enable us to measure<br /> desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.<br /><br /> Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1<br /> adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic<br /> responses to dobutamine over time.